Hideyuki Ohshimo

Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators

Tetsuhiko Shirasaka, Yuji Shimamato, Hideyuki Ohshimo et al. · Anti-Cancer Drugs · 1996 · 819 citations

Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo

Tetsuhiko Shirasaka, Yuji Shimamoto, Hideyuki Ohshimo et al. · Cancer Chemotherapy and Pharmacology · 1993 · 152 citations

Oncology, Medicine, Pharmacology +11

A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA

Tomohiro Emura, Norihiko Suzuki, Masahiro Yamaguchi et al. · International Journal of Oncology · 2004 · 119 citations

Antitumor Activity, Molecular Biology, Pathology +20

Preclinical antitumor efficacy of S-1: a new oral formulation of 5-fluorouracil on human tumor xenografts.

M Fukushima, Hirofumi Satake, Junji Uchida et al. · International Journal of Oncology · 1998 · 105 citations

Tumor Biology, Tumor Xenografts, Oncology +14

An optimal dosing schedule for a novel combination antimetabolite, TAS-102, based on its intracellular metabolism and its incorporation into DNA

Tomohiro Emura, Fumio Nakagawa, Akio Fujioka et al. · International Journal of Molecular Medicine · 2004 · 85 citations

Pharmaceutical Science, Chemical Biology, Culture Medium +21